IMMUNOME INC (IMNM)
NASDAQ • Healthcare
$27.56
+$0.16 (+0.6%)
Market open
Last close at August 18, 2026 at 20:00 UTC
Fundamentals Charts
About IMMUNOME INC
Name
IMMUNOME INC
CEO
Clay Siegall
Website
Industry
Healthcare
Year Founded
2006
Employees
206
Immunome, Inc. (NASDAQ: IMNM) is a Biotechnology company in the healthcare sector developing oncology therapeutics in the United States. The company is a small-cap drug developer focused on antibody-drug conjugates and related cancer programs, with Varegacestat, IM-1021, and other pipeline assets spanning clinical and preclinical stages.
Fundamentals & Financials
Revenue (TTM)
$0
Net Income (TTM)
-$254.3M
EPS (TTM)
-$2.54
ROA (TTM)
-44.98%
Current Ratio
15.08
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings Calendar
Stay Ahead of the Market
Get premium market insights delivered directly to your inbox.
Quote Summary
Previous CloseDay Range$27.56$26.76 - $27.69
52 Week RangeAvg. Volume$8.66 - $28.621M
Market Cap$2.7B
Peers & Related Assets
SYRESPYRE THERAPEUTICS INC
$107.82+3.1%
CLDXCELLDEX THERAPEUTICS INC
$41.79-0.3%
VERAVERA THERAPEUTICS INC CLASS A
$32.28+2.1%
BHVNBIOHAVEN LTD
$13.57-6.2%
ABCLAbCellera Biologics Inc.
PHVSPharvaris N.V.
ZBIOZENAS BIOPHARMA INC
NTLAINTELLIA THERAPEUTICS INC
MAZEMAZE THERAPEUTICS INC
UPBUPSTREAM BIO INC